Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital... by Jonas Michel Wolf, Bianca Borges, Pamela Fagundes, Vinicius de Souza, Aline Brenner, Helena Petek, William dos Santos, Juçara Maccari, Vania Rohsig, Mohamed Mutlaq, Luiz Nasi

Get full text